Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives.

J Hepatocell Carcinoma · 2019 · PMC6511249 · PMID 31123667

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

78 Although patients treated with tigatuzumab plus sorafenib had numerically longer median PFS and overall survival than those treated with sorafenib alone, the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.